低度近视眼内虹膜固定型有晶状体眼人工晶状体长期结局:十年以上随访的回顾性分析
回顾性单中心病例系列纳入2009至2019年SE<-6.00D的155眼(96例)植入Artisan或Artiflex pIOL,长期分析仅纳入无内眼手术史的Artiflex眼103眼,平均随访6.55±4.08年;结果显示Artiflex pIOL在低度近视中有效、可预测、稳定且安全,4眼(2.58%)需取出IOL。
要点
- 平均随访6.55±4.08年,末次随访71%和87%的眼在目标SE±0.50D和±1.00D内。
- 术后散光<1.00D者占93%,1年有效性指数0.90、安全性指数1.02,随时间保持稳定(P=.140和P=1.000)。
- 年均ECD丢失38.6 cells/mm²/y(年化百分比1.11%),IOP保持稳定,4眼(2.58%)需取出IOL。
核心结论
- 随访超过10年的长期结果表明,Artiflex pIOL植入对SE<-6D的低度近视患者有效、可预测、稳定且安全。
研究设计与样本
- 回顾性、单中心病例系列。
- 2009至2019年间共155眼(96例)SE<-6.00D患者植入Artisan或Artiflex pIOL;长期分析仅纳入无内眼手术史且接受Artiflex晶状体的103眼。
- 术前及每年术后评估包括UDVA、CDVA、有效性指数、安全性指数、显然验光、SE、ECD和IOP,并记录植入临床指征,采用描述性统计。
主要发现
- 术前平均SE为-4.64±0.92D,柱镜为-0.86±0.76D;平均随访6.55±4.08年(范围1-15年)。
- 最常见植入指征为地形图改变(40.4%)、中央角膜厚度<500µm(21.1%)和稳定期圆锥角膜(8.5%)。
- 末次随访时,71%的眼在目标SE矫正±0.50D内,87%的眼在±1.00D内;术后散光<1.00D者占93%。
- 1年有效性指数为0.90、安全性指数为1.02,随时间保持稳定(P=.140和P=1.000)。
- 年均ECD丢失38.6 cells/mm²/y,对应年化百分比丢失1.11%;IOP全程稳定;4眼(2.58%)需取出IOL。
关键数值与推荐
- 植入对象为SE<-6.00D的低度近视患者,接受Artisan或Artiflex pIOL。
- 长期分析仅纳入无内眼手术史且接受Artiflex晶状体的眼(n=103)。
- 有效性指数定义为术后UDVA/术前CDVA,安全性指数定义为术后CDVA/术前CDVA。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the clinical indications and long-term outcomes-specifically efficacy, safety, predictability, and stability-of iris-fixated anterior chamber phakic intraocular lenses (pIOLs) in patients with low myopia spherical equivalent (SE) <-6.00 diopters (D). DESIGN: Retrospective, single-center case series. SUBJECTS: A total of 155 eyes from 96 patients with SE < -6.00 D underwent implantation with either Artisan or Artiflex pIOLs between 2009 and 2019. For long-term analysis, only eyes without prior intraocular surgery that received Artiflex lenses were included (n = 103). METHODS: Preoperative and annual postoperative assessments included uncorrected (UDVA) and corrected distance visual acuity (CDVA); efficacy index (postoperative UDVA/preoperative CDVA) and safety index (postoperative CDVA/preoperative CDVA); manifest refraction, SE, endothelial cell density (ECD), and intraocular pressure (IOP). Clinical indications for implantation were recorded. Descriptive statistics were conducted. MAIN OUTCOME MEASURES: Frequency of clinical indications for implantation, visual acuity (UDVA, CDVA), manifest refraction including SE and astigmatism, refractive predictability and long-term stability, ECD, IOP, and incidence of adverse events. RESULTS: The mean preoperative SE was -4.64 ± 0.92 D and cylinder -0.86 ± 0.76 D. The average follow-up was 6.55 ± 4.08 years (range, 1-15 years). Topographic alterations (40.4%), central corneal thickness <500 µm (21.1%), and stable keratoconus (8.5%) were the most common indications. At final follow-up, 71% and 87% of eyes were within ±0.50 D and ±1.00 D of the attempted SE correction, respectively. Postoperative astigmatism was <1.00 D in 93% of eyes. Efficacy and safety indices were 0.90 and 1.02 at 1 year and remained stable over time (P = .140 and P = 1.000, respectively). The mean annual ECD loss was 38.6 cells/mm²/y, corresponding to an annualized percentage loss of 1.11%. IOP remained stable throughout follow-up. Four eyes (2.58%) required IOL explantation. CONCLUSIONS: Over more than 10 years of follow-up, long-term results indicate that Artiflex pIOL implantation is effective, predictable, stable, and safe in patients with low myopia <-6 D of SE.
引用
- Gómez Plaza D, González L, Güell JL, et al. Long-Term Outcomes of Iris-Fixated Phakic Intraocular Lenses in Low Myopia: A Retrospective Analysis With Over a Decade of Follow-up. Am J Ophthalmol. 2025. PMID: 40850455. doi:10.1016/j.ajo.2025.08.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。